GLENMARK Charts, Analysis and Tips

home > pharma-and-healthcare > pharmaceuticals > glenmark

Technical Analysis

Technical Strength: 7.1 / 10
Indicator Analysis Signal (0 - 10) Chart
RSI (?) RSI is 74.3. According to RSI analysis, glenmark is overbought. 3.0 GLENMARK RSI Chart
MACD (?) MACD: 16.3 and Signal Line: 14.9. According to MACD analysis, a bullish crossover just happend and it's a positive signal. But note that MACD is already positive. 8.0 GLENMARK MACD Chart
Simple Moving Average (?) According to simple moving average analysis, glenmark is in a uptrend. Support level is at 344. 9.0 GLENMARK Simple Moving Average Chart
Exponential Moving Average (?) According to exponential moving average analysis, glenmark is in a uptrend. Support level is at 348. 9.0 GLENMARK Exponential Moving Average Chart
Bollinger Bands (?) %b is 1.27. According to bollinger bands, glenmark has hit the upper band which is a positive signal. 9.0 GLENMARK Bollinger Bands Chart
Fibonacci Retracement (?) According to fibonacci retracement, price is above all levels. Major support is at 367.5122 and 359.5. Resistance level is 393.45. 6.5 GLENMARK Fibonacci Retracement Chart
Average True Range (?) ATR: 16.8 NA GLENMARK Average True Range Chart
Average Directional Index (?) ADX is 41.2 which means GLENMARK is in a trend. NA GLENMARK Average Directional Index Chart
Note: Technical Analysis updated at 7PM on every trading day.
End-of-Day Share Price - NSE
June 02, 2020
Open Price 373.0
High Price 393.45
Low Price 372.1
Close Price 388.7
Absolute Change 19.95
Percentage Change 5.41%
Weekly Change 11.6%
Monthly Change 15.2%
Yearly Change -31.8%
52-week high 581.75
52-week low 161.65
Corporate Actions
ExDate Purpose
September 19, 2019 AGM/DIV-RS 2 PER SH
September 19, 2018 AGM/DIV-RS 2 PER SHARE
August 03, 2016 ANNUAL GENERAL MEETING
See all Corporate Actions
Volume Chart
Real time prices can be delayed by 20 minutes. Prices are refreshed from our server automatically after 1 minute. If NSE real time price is not available then BSE real time prices are provided. Volume displayed might not be correct..

Fundamental Analysis

Beta (?)0.611
Confidence in Beta1.28%
Market Capital Rs. 10545.0 Cr
Whenever available, consolidated financial results are used. For details, see here.
Stock Deliverable Quantity and Daily Volatility
Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
Deliverable Quantity (?) 02 June 2020: Deliverable Quantity:1.21e+06 NA GLENMARK Deliverable Quantity Chart
Annualized Daily Volatility (Spot Price) (?) 02 June 2020: Daily Volatility:0.6457 NA GLENMARK Annualized Daily Volatility (Spot Price) Chart

Futures & Options Analysis

Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
PCR (?) 02 June 2020: PCR_OI:0.555 PCR:0.298 NA GLENMARK PCR Chart
Option Pain (?) 02 June 2020: Max Pain:350.0 NA GLENMARK Option Pain Chart
Premium (?) 02 June 2020 Premium: -0.3 Futures OI:3568600.0 NA GLENMARK Premium Chart
Option_MAX_OI (?) 02 June 2020: Price:388.7 Put with maximum OI:350.0 Call with maximum OI:400.0 NA GLENMARK Option_MAX_OI Chart

Futures - NSE

Expiry Date Close Price Open Interest Number of Trades No of Contracts Underlying Closing Price
June 25, 2020 388.4 3568600.0 9011.0 9011.0 388.7
July 30, 2020 390.45 87400.0 46.0 46.0 388.7
August 27, 2020 347.45 0.0 0.0 0.0 388.7

Announcements

October 01, 2018 Shareholders meeting Proceedings and Scrutinizer''s Report of the 40th Annual General Meeting {AGM) of Glenmark Pharmaceuticals Limited (''the Company'') held on September 28, 2018
August 13, 2018 News Clarification The Exchange has sought clarification from the Company with respect to news item captioned- True North in talks to buy into Glenmark API biz for Rs 1500 crIn this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
See all Announcements

Board Meetings

Date Meeting Date Purpose
February 12, 2020 February 14, 2020 Fund Raising We have to inform you that the Board of Directors of the Company, at its meeting scheduled on February 14, 2020, will, inter-alia, consider and evaluate proposals for raising of funds either by issuance of bonds / debentures / non-convertible debt instruments or any other securities or any combination thereof, of any of the above, for refinancing of bonds/FCCBs/loans, in accordance with the FEMA ECB Guidelines, and other applicable regulations, guidelines and laws of India, and subject to all necessary regulatory, statutory and shareholder approvals, as may be required.
February 01, 2020 February 14, 2020 Financial Results To consider and approve the financial results for the period ended December 31, 2019
See all Board Meetings

Get Clearnifty's Android App.

Get clearnifty on Google Play
Get clearnifty on Google Play